The Acquisition - Cerba Research

The Canada-based contract research organization (CRO) is widely recognized for its integrated bioanalytical and global central laboratory services, with more than 25 years of experience supporting pharmaceutical and biotech companies in their drug development programs. Click here to learn more about CIRION acquisition by Cerba Research.

What Does This Mean For You?

Extended Footprint

CIRION’s presence in North America strengthens our global reach, opening up new possibilities for Cerba Research to work, collaborate and make an impact throughout the United States and Canada.

Improved Capability

CIRION strengthens our ability to support drug development from the preclinical to post-approval phase, meaning that together, we can provide our customers with best-in-class scientific input and offer even greater critical flexibility for their drug development programs.

Added Expertise

CIRION’s deep experience in developing, optimizing, and validating immunogenicity methods, as well as its specialism in biologics and biosimilars, adds valuable new expertise to the Cerba Research portfolio.

How Does This Benefit Cerba Research Customers?

CIRION offers global central laboratory and bioanalytical services to evaluate new therapies throughout the drug development cycle, with particular expertise in pharmacokinetic (PK) and immunogenicity techniques.

Other benefits include:

Working relationships with the world’s top 10 biopharma companies.
College of American pathologists (CAP) and Clinical laboratory improvement amendments (CLIA) accredited.
Involvement in 270+ trials since 2010 (29% in oncology).
Developed and validated 300+ anti-drug antibody (ADA) assays, 100+ PK assays, and 100+ neutralizing antibody (NAb) assays.

How Does This Benefit CIRION Customers?

By joining Cerba Research, CIRION has become part of the leading global specialty, central laboratory and specialist diagnostic solutions provider. Together, our combined strengths will offer our customers greater expertise, specialties, data, and reach.

Other benefits include:

1000+ labs and immunohistochemistry (IHC) centers of excellence located around the world.
Flow cytometry hubs in Europe, the United States, and Asia Pacific.
Advanced sequencing techniques and specialty testing.
Data from 50 million patients worldwide.
Specialized in-house global logistics.

We Value Our Partnership

We’re excited to welcome CIRION’s highly qualified staff as part of our expert team, and we look forward to this new chapter in our company’s history delivering continued success for our customers.